Scholarlink

Background <p>Hip arthroplasty is effective for advanced osteoarthritis but poses a high venous thromboembolism (VTE) risk without prophylaxis; this study aimed to evaluate whether aspirin is as effective and safe as oral anticoagulants (OACs) for VTE prevention in this setting.</p> Methods <p>PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for studies up to June 01, 2024. The primary outcome was VTE incidence, including deep vein thrombosis (DVT) and pulmonary embolism (PE); secondary outcomes included bleeding and wound complications.</p> Results <p>Six RCTs involving patients undergoing hip arthroplasty were included. The pooled results demonstrated that aspirin had a comparable effect to OACs in preventing VTE (RR 0.90, 95% CI 0.63–1.29), with no significant differences observed in the incidence of DVT or PE. Additionally, no notable differences between the two groups in terms of bleeding risk or wound-related complications, although these safety outcomes were reported in fewer studies. Importantly, subgroup analyses across all pre-specified factors consistently supported the main findings, and no heterogeneity was observed in any outcome (I<sup>2</sup> = 0% for all analyses).</p> Conclusions <p>Based on existing RCT evidence, aspirin is as effective and safe as OACs for preventing VTE, DVT, and PE after hip arthroplasty, without increasing adverse events. The reliability of our conclusion is strengthened by the absence of heterogeneity in all our results, including those from subgroup analyses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aspirin as a viable alternative to oral anticoagulants for VTE prevention after hip arthroplasty: a meta-analysis of randomized clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Guoyin Zhang,
  • Lingqin Huang,
  • Xiaoguang Xu,
  • Yu Yang,
  • Xiaofang Ying,
  • Dawei Han

摘要

Background

Hip arthroplasty is effective for advanced osteoarthritis but poses a high venous thromboembolism (VTE) risk without prophylaxis; this study aimed to evaluate whether aspirin is as effective and safe as oral anticoagulants (OACs) for VTE prevention in this setting.

Methods

PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for studies up to June 01, 2024. The primary outcome was VTE incidence, including deep vein thrombosis (DVT) and pulmonary embolism (PE); secondary outcomes included bleeding and wound complications.

Results

Six RCTs involving patients undergoing hip arthroplasty were included. The pooled results demonstrated that aspirin had a comparable effect to OACs in preventing VTE (RR 0.90, 95% CI 0.63–1.29), with no significant differences observed in the incidence of DVT or PE. Additionally, no notable differences between the two groups in terms of bleeding risk or wound-related complications, although these safety outcomes were reported in fewer studies. Importantly, subgroup analyses across all pre-specified factors consistently supported the main findings, and no heterogeneity was observed in any outcome (I2 = 0% for all analyses).

Conclusions

Based on existing RCT evidence, aspirin is as effective and safe as OACs for preventing VTE, DVT, and PE after hip arthroplasty, without increasing adverse events. The reliability of our conclusion is strengthened by the absence of heterogeneity in all our results, including those from subgroup analyses.